Opko Health OPK Capitalized Research And Development In Process
Capitalized Research And Development In Process at other companies
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept opk:CapitalizedResearchAndDevelopmentInProcess.
The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opko Health's capitalized research and development in process.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opko Health's capitalized research and development in process?
- Opko Health (OPK) reported capitalized research and development in process of $195M in Q1 2026.
- How has Opko Health's capitalized research and development in process changed year-over-year?
- Opko Health's capitalized research and development in process decreased by 0.0% year-over-year, from $195M to $195M.
- What is the long-term trend for Opko Health's capitalized research and development in process?
- Over 3 years (2022 to 2025), Opko Health's capitalized research and development in process has grown at a 0.0% compound annual growth rate (CAGR), from $195M to $195M.
- What does capitalized research and development in process mean?
- This represents the value of research and development costs that have been capitalized as an asset on the balance sheet rather than expensed as incurred. It reflects investments in long-term projects or intellectual property that are expected to provide future economic benefits to the company. Monitoring this balance helps investors assess the company's commitment to innovation and the potential future value of its development pipeline.